Beth Overmoyer, MD, FACP
Clinician + Researcher
Title(s)
- Director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute
- Institute Physician, Dana Farber Cancer Institute
- Assistant Professor of Medicine, Harvard Medical School
Location(s)
- Dana-Farber Cancer Institute
- 450 Brookline Avenue
- Boston, MA, 02215
- United States of America
- Phone: 617.632.6973
- Fax: 617.632.1930
Research and Clinical Interests
IBC-Focused Research
Dr. Overmoyer launched the Inflammatory Breast Cancer (IBC) Program at the Dana-Farber Cancer Institute in 2009, where she continues to serve as its Director focusing on the development of IBC research programs and clinical trials. She began her oncology career in 1989 at the University of Pennsylvania, where she trained in breast cancer and began her studies on inflammatory breast cancer. She went on to develop the breast cancer program at the Cleveland Clinic and later became the Director of Breast Cancer Research and the Director of the Clinical Trials Core at the Case Comprehensive Cancer Center in Cleveland. She came to the Dana Farber Cancer Institute in 2007 and is an Institute Physician and Assistant Professor of Medicine at Harvard Medical School.
Clinical interests
- Breast Cancer Clinical Trials
- Breast Cancer Genetics
- Inflammatory Breast Cancer
- Systemic Treatment of Breast Cancer: Early Stage and Metastatic
Education and Board Certifications
MD
Case Western Reserve University School of Medicine, Cleveland, OH (1986)
Internship
Hospital of the University of Pennsylvania, Philadelphia, PA, Internal Medicine (1989)
Residency
Hospital of the University of Pennsylvania, Philadelphia, PA, Internal Medicine (1989)
Fellowship
Hospital of the University of Pennsylvania, Philadelphia, PA, Hematology/Oncology (1993)
Board Certification(s)
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Medical Oncology
American Board of Internal Medicine - Internal Medicine
Years in Practice
31
Affiliations and Memberships
Recent Publications
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional ManagementAnnals of Surgical Oncology; August 2015
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Oncologist; January 2017
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast CancerAnnals of Surgical Oncology; May 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Association of American Physicians and Surgeons; June 2017
Clinical Trials
NCI.gov – NCT02876302: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer NCI.gov – NCT02623972: A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer NCI.gov – NCT01796197: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for inflammatory breast cancer DF/HCC 12-156: Clinical and Pathological Correlation of Inflammatory Breast Cancer Imaging
Affiliated IBC-IC Center(s)
- Dana-Farber Cancer Institute Inflammatory Breast Cancer Program
- Boston, MA, 02215
- Research + Treatment Center
Join IBC-IC
Become part of our international consortium of researchers, clinicians, advocates and centers worldwide dedicated to ending IBC.
Join >IBCIC.org makes every effort to keep researcher information as up-to-date as possible.
Contact this researcher to confirm any information regarding his or her profile.